Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Five Under 5: Top Oncology Videos for the Week of 3/2

March 9th 2025

The top 5 OncLive videos of the week cover insights in TGCT, NSCLC, TNBC, AML, and MDS.

The OncFive: Top Oncology Articles for the Week of 3/2

March 9th 2025

Tislelizumab regimen wins approval in ESCC, perioperative durvalumab plus chemotherapy boosts EFS in gastric/GEJ cancer, and more from OncLive this week.

FDA Grants Orphan Drug Designation to Bexmarilimab for Myelodysplastic Syndromes

March 4th 2025

The FDA has granted orphan drug designation to bexmarilimab for myelodysplastic syndromes.

Lisaftoclax Plus Azacitidine Shows Clinical Activity and Manageable Safety in Higher-Risk MDS

March 4th 2025

Lisaftoclax plus azacitidine demonstrated clinical activity and was safe in higher-risk MDS.

Rusfertide Meets Response End Point in Phlebotomy-Dependent Polycythemia Vera

March 3rd 2025

Rusfertide improved responses vs placebo in phlebotomy-dependent polycythemia vera.

Divesiran Is Tolerable and Shows Positive Early Signals in Polycythemia Vera

February 26th 2025

The siRNA divesiran was well-tolerated and reduced the number of phlebotomies that were required in patients with polycythemia vera.

Ruxolitinib Plus SOC Prophylaxis Is Associated With Lower Rates of GVHD in Myelofibrosis

February 14th 2025

Ruxolitinib plus standard GVHD prophylaxis reduced GVHD in patients with myelofibrosis undergoing transplant.

Dr Kishtagari on Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

February 13th 2025

The MANIFEST-2 trial showed that pelabresib/ruxolitinib led to greater spleen volume reduction and improved anemia vs ruxolitinib alone in myelofibrosis

MD Anderson Study Resumes With Seclidemstat/Azacitidine in MDS/CMML

February 7th 2025

The combination of seclidemstat and azacitidine will resume study in a phase 1/2 trial in patients with MDS and CMML following a partial clinical hold.

Dr Al Malki on Reducing Relapse Risk in Patients with MDS Undergoing Haplo-HSCT

February 7th 2025

Monzr M. Al Malki, MD, discusses reducing relapse risk in patients undergoing haploidentical hematopoietic stem cell transplantation.

Type II JAK Inhibitor AJ1-11095 Under Phase 1 Investigation in Myelofibrosis

February 5th 2025

AJ1-11095 is being evaluated in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia.

Rovadicitinib Shows Safety, Clinical Activity After Ruxolitinib Intolerance in Myelofibrosis

February 5th 2025

The JAK/ROCK inhibitor rovadicitinib may provide a safe and effective new treatment option for patients with myelofibrosis who progressed on ruxolitinib.

Dr Sekeres on the Association Between Smoking and Disease Progression in MDS

February 5th 2025

Mikkael A. Sekeres, MD, discusses the association between smoking intensity, genetic mutations, and disease progression in myelodysplastic syndromes.

Second-Line Fedratinib Produces Early Platelet Count Improvements in Myelofibrosis

February 5th 2025

Fedratinib showed early improvements in platelet count in patients with myelofibrosis.

The Potential of Oral HMAs in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the potential for the use of oral HMAs in MDS.

Where Imetelstat Fits Into the Paradigm for Transfusion-Dependent Anemia in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the implications of the FDA approval of imetelstat for transfusion-dependent anemia in MDS.

Other Potential Roles for Luspatercept in MDS And Beyond

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss other potential roles for luspatercept in MDS and beyond.

Long-Term Transfusion Independence Data for Luspatercept vs ESAs in Lower-Risk MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss long-term transfusion independence data for luspatercept in MDS.

Optimal Goals for Anemia and Transfusion Independence in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on treatment goals for anemia and transfusion independence in MDS.

Clinical Implications of FDA Approval of Luspatercept for Anemia in ESA-Naive Lower-Risk MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on the FDA approval of luspatercept in ESA-naive lower-risk MDS.